Hasil Pencarian (16004)
Halaman 153 / 321Ganaplacide is under investigation in clinical trial NCT03167242 (Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria).
Ganaxolone is the 3?-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids.[A3197] Endogenous neurosteroids, which comprise certain metabolites…
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Gandotinib has been used in trials studying the treatment of Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders, among others.
Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.
Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. Ganirelix is indicated for controlled ovarian hyperstimulation in assisted reproduct…
Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.
Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (A?) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD patho…
Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).
Garcinia gummi-gutta fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Garden snail mucin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and mino…
Garivulimab is under investigation in clinical trial NCT03379259 (Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors).
Deskripsi belum tersedia.
Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin…
Gatipotuzumab is under investigation in clinical trial NCT01899599 (Pankomab-gex™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer).
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is o…
Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the en…
Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).
GB-115 is under investigation in clinical trial NCT05586789 (A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders).
GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
GB1211 is an orally active galectin-3 (Gal-3) inhibitor.
A selective inhibitor of dopamine uptake.[A252997]
Deskripsi belum tersedia.
GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036]. It is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional prot…
GC-376 is a 3C-like protease (3CL<sup>pro</sup> or M<sup>pro</sup>) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells[A219036]. The compound is known as a direct acting antiv…
GC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.
GDC-0152 has been used in trials studying the treatment of Solid Cancers.
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
GDC-0623 has been used in trials studying the treatment of Solid Cancers.
ARN-810 has been used in trials studying the basic science and treatment of Breast Cancer.
CUDC-427 has been used in trials studying the treatment of LYMPHOMA and Solid Cancers.
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Deskripsi belum tersedia.